Duchenne muscular dystrophy is characterized by progressive muscle weakness and early death resulting from dystrophin deficiency. Loss of dystrophin results in disruption of a large dystrophin glycoprotein complex, leading to pathological calcium (Ca 2+ )-dependent signals that damage muscle cells [1] [2] [3] [4] [5] . We have identified a structural and functional defect in the ryanodine receptor (RyR1), a sarcoplasmic reticulum Ca 2+ release channel, in the mdx mouse model of muscular dystrophy that contributes to altered Ca 2+ homeostasis in dystrophic muscles. RyR1 isolated from mdx skeletal muscle showed an age-dependent increase in S-nitrosylation coincident with dystrophic changes in the muscle. RyR1 S-nitrosylation depleted the channel complex of FKBP12 (also known as calstabin-1, for calcium channel stabilizing binding protein), resulting in 'leaky' channels. Preventing calstabin-1 depletion from RyR1 with S107, a compound that binds the RyR1 channel and enhances the binding affinity of calstabin-1 to the nitrosylated channel, inhibited sarcoplasmic reticulum Ca 2+ leak, reduced biochemical and histological evidence of muscle damage, improved muscle function and increased exercise performance in mdx mice. On the basis of these findings, we propose that sarcoplasmic reticulum Ca 2+ leak via RyR1 due to S-nitrosylation of the channel and calstabin-1 depletion contributes to muscle weakness in muscular dystrophy, and that preventing the RyR1-mediated sarcoplasmic reticulum Ca 2+ leak may provide a new therapeutic approach.
Duchenne muscular dystrophy is characterized by progressive muscle weakness and early death resulting from dystrophin deficiency. Loss of dystrophin results in disruption of a large dystrophin glycoprotein complex, leading to pathological calcium (Ca 2+ )-dependent signals that damage muscle cells [1] [2] [3] [4] [5] . We have identified a structural and functional defect in the ryanodine receptor (RyR1), a sarcoplasmic reticulum Ca 2+ release channel, in the mdx mouse model of muscular dystrophy that contributes to altered Ca 2+ homeostasis in dystrophic muscles. RyR1 isolated from mdx skeletal muscle showed an age-dependent increase in S-nitrosylation coincident with dystrophic changes in the muscle. RyR1 S-nitrosylation depleted the channel complex of FKBP12 (also known as calstabin-1, for calcium channel stabilizing binding protein), resulting in 'leaky' channels. Preventing calstabin-1 depletion from RyR1 with S107, a compound that binds the RyR1 channel and enhances the binding affinity of calstabin-1 to the nitrosylated channel, inhibited sarcoplasmic reticulum Ca 2+ leak, reduced biochemical and histological evidence of muscle damage, improved muscle function and increased exercise performance in mdx mice. On the basis of these findings, we propose that sarcoplasmic reticulum Ca 2+ leak via RyR1 due to S-nitrosylation of the channel and calstabin-1 depletion contributes to muscle weakness in muscular dystrophy, and that preventing the RyR1-mediated sarcoplasmic reticulum Ca 2+ leak may provide a new therapeutic approach.
Duchenne muscular dystrophy (DMD), the most common X-linked disorder (affecting 1 in 3,500 male births), typically results in death as a result of respiratory or cardiac failure by age 30 (ref. 6) . Loss of dystrophin leads to disruption of the dystrophin glycoprotein complex (DGC) in the sarcolemmal membrane that connects the cytoskeleton and contractile apparatus of muscle cells to the extracellular matrix and basement membrane 7, 8 . Cytoplasmic calcium homeostasis in dystrophic muscle fibers is abnormal 1, 3, 9 . Disruption of the DGC impairs sarcolemmal membrane integrity and results in increased influx of Ca 2+ into the muscle across the sarcolemma, which has been attributed to Ca 2+ leak channels in the plasma membrane 5 , microscopic membrane tears 3, 10 , mechanosensitive Ca 2+ channels 11 , or store-operated Ca 2+ channels activated by sarcoplasmic reticulum Ca 2+ depletion 12, 13 . An elevated cytoplasmic calcium concentration ([Ca 2+ ] cyt ) is implicated in the pathophysiology of protein degradation in mdx muscle 4 and cell death 14 . A downstream effect of elevated [Ca 2+ ] cyt is activation of calpains (Ca 2+ -dependent neutral proteases) 15 . Transgenic expression of calpastatin in the dystrophic mouse partially rescues myofiber damage 16 . It has been proposed that elevated [Ca 2+ ] cyt contributes to myofiber death at a rate that cannot be compensated for by recruitment of progenitor (satellite) muscle cells and regeneration and differentiation of new muscle cells 3 . Sarcoplasmic reticulum Ca 2+ reuptake is slowed in mdx myofibers, and a sarcoplasmic reticulum Ca 2+ leak of uncertain etiology has been reported 5, 11, 17 . The rate of Ca 2+ sparks in dystrophic fibers is increased, further suggesting that a defect in sarcoplasmic reticulum Ca 2+ release may be present in muscular dystrophy 18 .
An approximately 80% reduction in neuronal nitric oxide synthase (nNOS) messenger RNA and protein levels has been reported in dystrophin-deficient muscle 19, 20 and has been implicated in the pathophysiology of muscular dystrophy 21 . RyR1 contains multiple cysteine residues 22 that can be modified at physiological pH by either S-nitrosylation or S-glutathionylation [23] [24] [25] . Cyclic GMP-independent, nitric oxide-mediated modification of RyRs increases channel activity in single-channel measurements 22 . Exogenous S-nitrosylation of RyR1 has been shown to reduce the affinity of calstabin-1 binding to purified sarcoplasmic reticulum vesicles 26 .
We hypothesized that defects in the macromolecular complex containing RyR1 may contribute to the abnormalities in [Ca 2+ ] cyt in muscular dystrophy. To test this hypothesis, we assessed the composition of the RyR1 macromolecular complex 27, 28 from hind limb extensor digitorum longus (EDL) muscle of mdx mice. Histological evidence of muscular dystrophy is evident by 35 d of age. In mice at this age, there was a significant increase in S-nitrosylation of cysteine residues in RyR1 from mdx mice compared to age-matched wild-type (WT) littermates (Fig. 1a,b) . Increased RyR1 S-nitrosylation correlated with depletion of calstabin-1 from the RyR1 complex (Fig. 1a,b) . No differences in S-nitrosylation, protein kinase A (PKA) phosphorylation of RyR1 (at Ser2844) or calstabin-1 bound to the RyR1 complex were observed between mdx mice and WT littermates at 7 and 21 d of age (Fig. 1a,b) . Moreover, there was no increase in PKA phosphorylation of RyR1 at Ser2844 in mdx mice at any age examined (Fig. 1a,b) . Total amounts of calstabin-1 in whole muscle lysate were not altered in mdx muscle at any age, indicating that the reduced calstabin-1 binding to RyR1 is due to reduced binding to RyR1 rather than altered expression of calstabin-1 (Fig. 1c) . Immunoprecipitation of RyR1 was specific and efficient, leaving little RyR1 in the voided fraction ( Supplementary Fig. 1 online) . Thus, increased RyR1 Snitrosylation and depletion of calstabin-1 correlated with muscular dystrophy in mdx mice.
Exogenous S-nitrosylation of RyR1 with nitric oxide donors resulted in depletion of calstabin-1 from the channel (Fig. 2a) , as previously reported 26 . To identify the basis for the increased S-nitrosylation of RyR1, we determined the abundance of nitric oxide synthase isoforms by immunoblotting WT and mdx EDL muscles for inducible NOS (iNOS), endothelial NOS (eNOS) and neuronal NOS (nNOS) expression (Fig. 2b) . iNOS amounts were significantly increased in EDL muscles from mdx mice 35 d and older and were essentially undetectable in WT muscle. eNOS expression was decreased in mdx skeletal muscle compared to WT littermates. nNOS expression was decreased in mdx tissue. RyR1 and iNOS (but not eNOS) co-immunoprecipitated from mdx EDL muscle (Fig. 2c,d ), but iNOS was not detected in immunoprecipitates from WT muscle generated with antibodies to either RyR1 or iNOS (data not shown). iNOS immunoprecipitated with RyR1 at 35 and 180 d of age (Fig. 2e) . Moreover, iNOS co-localized with RyR1 in mdx EDL muscle, whereas iNOS was not detected in WT EDL muscle (Fig. 2f) . These data suggest that iNOS is a component of the RyR1 macromolecular complex in mdx mice, but not in WT mice.
We have reported that RyR Ca 2+ release channel stabilizers, which we propose calling 'rycals' , inhibit depletion of calstabin-1 from RyR1 hyperphosphorylated by PKA 28, 29 . We hypothesized that treatment with S107, a stable, cell-permeable rycal 28 , begun as early as possible in mdx mice, would reduce the RyR1-mediated sarcoplasmic reticulum Ca 2+ leak induced by S-nitrosylation of RyR1 and calstabin-1 depletion and partially protect against muscle damage due to [Ca 2+ ] cytmediated calpain activation.
We randomized 4-5-week-old male mdx mice into groups receiving treatment with either S107 or vehicle (H 2 O) via a subcutaneous osmotic pump. After 2 weeks of treatment, forelimb grip strength was assessed. There was significant improvement in grip strength in 4 WT mdx the S107-treated group (n ¼ 14; P o 0.001 versus vehicle controls (n ¼ 14); Fig. 3a) . Normalized for body weight, grip strength was significantly improved in mdx mice treated with S107 (P o 0.01 versus vehicle controls, t-test analysis of two independent, pairmatched and blinded cohorts; Fig. 3b ). The serum concentration of creatine kinase, a marker of muscle necrosis, was significantly reduced by S107 treatment in mdx mice, suggesting a reduction in muscle damage (Fig. 3c) . Calpain levels in EDL hind limb muscle (determined by measuring the enzymatic activity of activatable calpain in the muscle) were also reduced by S107 treatment (Fig. 3d) , suggesting that inhibition of RyR1-mediated sarcoplasmic reticulum Ca 2+ leak may reduce Ca 2+ -activated proteolytic enzyme activity, leading to protection of dystrophic muscle against damage. Eccentric (lengthening) exercise such as downhill running is particularly difficult for mdx mice 30 . S107-treated mdx mice completed a 30-min downhill run at a higher rate than did vehicle-treated mice (nine of eleven mice versus three of ten, P o 0.05). Creatine kinase abundance was reduced in these mdx mice by treatment with S107 (6,200 versus 13,300 U l À1 in vehicle-treated mdx controls, P o 0.05), providing further evidence that S107 can improve function and reduce creatine kinase leak in mdx muscle. Calpain activation in EDL hind limb muscle in these mdx mice was reduced by S107 treatment (1,250 U mg À1 versus 2,100 U mg À1 in vehicle-treated mdx controls, P o 0.05), suggesting that stabilization of RyR1 reduced Ca 2+ leak and Ca 2+ -activated proteolytic enzyme activity. S107 treatment prevented depletion of calstabin-1 from S-nitrosylated RyR1 without affecting PKA phosphorylation of RyR1, S-nitrosylation of RyR1 or the levels of phosphodiesterase 4D3 (PDE4D3; Fig. 3e ,f) in the RyR1 macromolecular complex. NOS isoform expression in muscle was not altered by S107 treatment (Fig. 3g) . Treatment of mdx mice with S107 via osmotic pump beginning at 4-5 weeks of age and continuing for up to 4 weeks resulted in improvement in the histological hallmarks of dystrophy. In the tibialis anterior hind limb muscle, there was a reduction in Evans blue dyepositive fibers (12.1 ± 2.8% in mdx mice treated with S107 (n ¼ 3) versus 26.3 ± 5.3% in vehicle-treated mdx mice (n ¼ 3, P o 0.05; Fig. 3h) ). Comparison of diaphragmatic muscle from mdx mice treated with S107 (n ¼ 5) to mdx mice treated with vehicle alone (n ¼ 4) showed a 28% reduction in the number of central nuclei (P o 0.05), a 50% reduction in the number of Evans blue-positive muscle fibers (P o 0.05) and a 32% increase in fiber cross-sectional area (P o 0.05; Fig. 3i ). These improvements in the histology of the dystrophic muscles correlated with improved muscle function and with decreased creatine kinase and calpain levels ( Fig. 3a-d) .
We subjected EDL muscle to eccentric contraction and determined the resulting force deficit, which we defined as the percentage decline in isometric force after one eccentric contraction. The decline in isometric force served as a functional indicator of contraction-induced mechanical injury to dystrophic muscle, as previously reported 30 . Force production during a tetanic contraction was recorded from EDL muscle in situ in anesthetized mice first in combination with an eccentric lengthening (to 115% of resting muscle length); then, after a 1-min rest, force production was recorded during a second tetanic contraction without eccentric stress (Fig. 4a) . Eccentric contraction in mdx muscle resulted in a marked reduction in force production compared to control muscles (Fig. 4b) . In mice treated for 7-10 d (g) Immunoblots for iNOS, eNOS and nNOS in EDL whole-muscle lysates from WT, mdx-veh, and mdx-S107 mice. For panels e-g, n ¼ 3 mice per group. (h) Representative images of DAPI-stained muscle sections from Evans blue dye-injected mice to assess muscle damage in control and S107-treated mice.
(i) Representative H&E-stained images from diaphragm of WT mice, mdx mice treated with vehicle or with S107 for 4 weeks as in h. For panels h and i, n ¼ 3 or more mice per group; at least three sections from each muscle were analyzed.
with S107 in their drinking water (B37.5 mg kg À1 d À1 ), this deficit in force production after one eccentric contraction was restored to the control value (Fig. 4b) . We thus hypothesized that impaired muscle function occurring during eccentric contractions in mdx mice was linked to defective RyR1 channel function, specifically to a leak of sarcoplasmic reticulum Ca 2+ via RyR1. To further test this hypothesis, we analyzed spontaneous Ca 2+ release events, or Ca 2+ sparks, in EDL muscle fibers from control WT mice and in mdx mice after one episode of mild eccentric contraction. The Ca 2+ spark frequency was significantly (P o 0.05) increased in muscle fibers from mdx mice compared to control mice ( Fig. 4c-f ). Other spatiotemporal properties of the sparks, including amplitude, rise time, decay time constant or spatial spread (full width at half maximum), were not different between the two groups (data not shown). Of note, there was no difference in spatiotemporal Ca 2+ spark properties between control and mdx mice in the absence of mechanical stress (that is, eccentric contraction), or between control muscle with and without eccentric contraction (data not shown). Thus, inhibition of calstabin-1 depletion from the RyR1 complex by S107 treatment of mdx mice reduced sarcoplasmic reticulum Ca 2+ leak via RyR1, as manifested by a reduction in Ca 2+ spark frequency (Fig. 4e,f) . We next tested whether treatment with S107 could improve the voluntary exercise of mdx mice. After acclimating mice for 5 d to a wheel placed in their cage, we measured the length of time they spent on the wheel and their average and maximal velocities over 72 h. Mdx mice treated with S107 spent significantly more time on the wheel and achieved B50% higher maximal velocities compared to mdx mice treated with vehicle alone (Fig. 4g) . In addition, as determined by in situ force measurements of EDL muscle, S107 treatment significantly (P o 0.001) increased specific force (Fig. 4h) and resistance to fatigue (determined as relative force during repeated tetanic stimulation; Fig. 4i ) in mdx muscle compared to vehicletreated mdx control values.
Taken together, our data show that RyR1 Ca 2+ release channels are leaky in mdx skeletal muscle owing to RyR1 hypernitrosylation, which depletes the RyR1 channel complex of the stabilizing subunit calstabin-1. Hypernitrosylation of RyR1 was associated with a marked increase in the expression of iNOS in the mdx muscle and formation of an iNOS-RyR1 complex. RyR1-mediated intracellular Ca 2+ leak was associated with increased concentrations of the Ca 2+ -activated protease calpain in mdx muscle that may contribute to the observed muscle damage, impaired muscle force and decreased exercise capacity in mdx mice. We have previously shown that calstabin-1 stabilizes the closed state of individual RyR1 channels 31 and mediates coupled gating between multiple RyR1 channels 32 . Both stabilization of the RyR1 closed state and coupled gating are likely to have roles in preventing aberrant sarcoplasmic reticulum Ca 2+ leak through RyR1 channels. Treatment with S107, which inhibits depletion of calstabin-1 from hypernitrosylated RyR1 channels in dystrophic muscle, reduced pathological sarcoplasmic reticulum Ca 2+ leak and calpain activation, protected against muscle damage, improved muscle force, reduced fatigue and improved grip strength and voluntary exercise in mdx mice.
Notably, these improvements were observed after 1 week (improved exercise capacity) or 4 weeks (histologic improvement) of S107 treatment, which is considerably faster than most genetic therapies. This suggests that the RyR1-mediated intracellular Ca 2+ leak is downstream of the genetic defects that cause muscular dystrophy (for example, dystrophin deficiency). Heat diagram indicates change in fluorescence as the ratio DF/F 0 . (f) Quantification of spark frequency in control WT mice, vehicle-treated mdx mice and mdx mice treated with S107 (three or four fibers per EDL muscle from five mice were examined for each condition; the numbers of sparks examined were 615, 2,586 and 883 in WT mice, vehicle-treated mdx mice and mdx mice treated with S107, respectively). Data are expressed as means ± s.e.m. (*P o 0.05 for WT versus vehicle-treated mdx mice or vehicle-treated mdx versus S107-treated mdx mice). (g) Effects of S107 treatment (0.25 mg ml -1 in the drinking water administered for 10 d before testing) on spontaneous physical activity of mdx mice. n ¼ 5 mice for each condition, * P o 0.05. (h) Specific force-frequency relationship of EDL muscle from the same groups as in g. (n ¼ 5 for each treatment group, P o 0.001 by a two-way analysis of variance comparing S107-treated versus vehicle-treated mdx mice). (i) EDL force during a fatigue protocol (30-Hz, 300-ms trains applied every second for 300 s). Force values are normalized to the force developed during the first train of the protocol. n ¼ 5 for each treatment group, P o 0.001 by a two-way analysis of variance comparing S107-treated versus vehicle-treated mdx mice. It has been suggested that RyR1 channel function may be regulated by S-nitrosylation, but, to date, the physiological consequences of this form of regulation in vivo have not been well understood. nNOS is the principal source of nitric oxide in skeletal muscle. It is localized at the plasma membrane, where an N-terminal GLGF peptide motif binds to the dystrophin complex via an interaction with syntrophin 19, 33 . Disruption of the DGC in DMD results in a selective loss of nNOS catalytic activity that is associated with its downregulation at the transcriptional level 19, 20 . Recently, decreased abundance of sarcolemmal-localized nNOS was shown to be linked to vasoconstriction and decreased physical activity after mild exercise (10-min downhill run) in mouse models including mdx mice, and treatment with a PDE5 inhibitor increased physical activity after mild exercise 34 . In contrast, iNOS expression is substantially increased in the skeletal muscle of both humans with DMD and mdx mice, and rescue of the mdx phenotype by adenoviral-mediated dystrophin or utrophin expression normalizes iNOS activity 35 . The concurrent downregulation of nNOS and upregulation of iNOS suggests that the latter could be a compensatory response. However, functional compensation may be precluded by differences in the subcellular localization of the two NOS isoforms. In muscular dystrophy, both the effects of increased nitrosative stress on the RyR1 complex and increased Ca 2+ influx across the plasma membrane due to disruption of the DGC may activate RyR1 channels. Depletion of the stabilizing subunit calstabin-1 (FKBP12) from the RyR1 channel due to nitrosative stress may render it particularly sensitive to Ca 2+ -mediated activation.
Therapeutic strategies for muscular dystrophy include gene therapy to replace dystrophin 36 , upregulation of the dystrophin homolog utrophin 37 , acceleration of the rate of muscle regeneration 38, 39 and exon skipping achieved via virus-mediated expression of antisense sequences linked to a modified U7 small nuclear RNA 40 . Stabilization of RyR1 by inhibiting sarcoplasmic reticulum Ca 2+ leak with a small molecule may provide an additional strategy to protect against muscle damage and improve function.
METHODS
Mice and treatment with S107. We obtained C57BL/10ScSc-Dmd mdx /J mice, referred to as mdx mice (stock number 001801) and C57BL/6J mice, referred to as WT mice, from Jackson Laboratories and bred them to obtain male mdx and WT littermate controls. We randomized the mice to groups receiving treatment with either S107 (for additional information on synthesis and specificity, see Supplementary Methods online and ref. 28) or vehicle (H 2 O). In some experiments, we subcutaneously implanted osmotic pumps (Alzet model 1004, 100 ml total volume, 0.11 ml h À1 delivery for B28 d, Durect) filled with H 2 O or S107 (80 mg ml À1 diluted in H 2 O) on the dorsal surface of each mouse by a horizontal incision at the neck for 2-4 weeks as indicated in the legend to Figure 3 . In other experiments, we added S107 to the drinking water (final concentration, 0.25 mg ml À1 ) as indicated in the legend to Figure 4 . The mice drank B3 ml per day (water consumption was variable, and we recorded water bottle and body weight to monitor consumption) for a daily dose of B0.75 mg (B37.5 mg kg À1 d À1 ), which resulted in a plasma S107 concentration of B35 ± 21 ng ml À1 (B140 nM, which we determined in the early morning to reflect higher water consumption during the night). We conducted all experiments in accordance with protocols approved by the Institutional Animal Care and Use Committees of Columbia University and Université Montpellier. All studies involving drug treatments, including analyses of function and histologic sections, were conducted by individuals blinded to the treatment status of the mice.
Immunoblotting. Membranes were incubated for 1-2 h at room temperature with primary antibody to RyR1 (RyR1-1327, an affinity-purified rabbit polyclonal antibody raised against a KLH-conjugated peptide with the amino acid sequence CAEPDTDYENLRRS, corresponding to residues 1327-1339 of mouse skeletal RyR1, with an additional cysteine residue added to the amino terminus), and affinity purified with the unconjugated peptide. This antibody specifically recognizes RyR1, as it does not react with RyR2 or RyR3 when used at a 1 in 2,500 or 1 in 5,000 dilution for immunoblotting and at a 1 in 250 dilution for immunoprecipitation (data not shown). We also used antibody to calstabin (1 in 2,500 in blocking buffer, LICOR Biosciences); phospho-epitopespecific antibody to human RyR2 phosphorylated on Ser2809 (1 in 5,000) 41 , which detects PKA-phosphorylated mouse RyR1 (on Ser2844) and RyR2 (on Ser2808); antibody to S-nitrosylated cysteine residues (1 in 1,000, Sigma); antibody to PDE4D3 (1 in 1,000) 42 ; and antibodies to iNOS (1 in 2,000, VWR), eNOS (1 in 2,000, VWR) and nNOS (1 in 1,000, VWR). For additional biochemical methods, including S-nitrosylation of RyR1 with Nor-3 and Noc-12, see Supplementary Methods.
Grip strength. We assessed forelimb grip strength after two weeks of treatment with S107 or vehicle. We allowed each mouse to grab a hold bar attached to a force transducer that records the peak force generated as the mouse is pulled by the tail horizontally away from the bar (model number 303500-M/C-1, TSE Systems). We performed five consecutive pulls separated by 15-s pauses between each pull. We calculated the absolute grip strength as the average of the peak forces recorded from the middle three pulls (in ponds, 1 pond ¼ B9.8 mN), and a normalized grip strength, which is the absolute grip strength divided by the body weight in grams.
Creatine kinase and calpain assay. We determined creatine kinase levels on the basis of absorbance change per minute by a commercial assay according to the manufacturer's instructions (Pointe Scientific). We diluted EDL muscle homogenates to a final concentration of 600 mg ml À1 , and we determined the calpain activity in the homogenate with a commercial assay according to the manufacturer's instructions (Calbiochem).
Measurement of extensor digitorum longus resistance to contractioninduced mechanical stress. We anesthetized mice (male, 40 d old) with 130 mg kg À1 ketamine and 20 mg kg À1 xylazine and immobilized them in the supine position on a surgical platform at 37 1C. We exposed the anterior region of the lower hind limb from the ankle to just above the knee and dissected free the distal tendons of the tibialis anterior and EDL. We tied the distal tendon of the EDL with a 4À0 nylon suture to the lever arm of a force transducer and length servomotor system (model 305B dual mode; Aurora Scientific), which was mounted on a mobile micrometer stage to allow fine incremental adjustments of muscle length. We kept the exposed muscles moist with a 37 1C isotonic saline drip. We stimulated the EDL indirectly via an electrode placed on the belly of the tibialis anterior. For details of the stimulation protocols, see Supplementary Methods. Calcium sparks. We acquired fluorescence images with a Zeiss LSM 510 META NLO confocal system equipped with a three-point 63Â water immersion objective (numerical aperture ¼ 1.2) operated in line-scan mode (1.5 ms per line, 3,000 lines per scan) along the longitudinal axis of the fibers. We excited Fluo-3 at 488 nm with an Argon laser and recorded the emitted fluorescence at 525 nm. Additional details of spark measurement are in the Supplementary Methods.
Voluntary exercise measurements. We evaluated voluntary exercise in mice by placing a 5.5-cm-wide by 12-cm diameter wheel in a 15 cm Â 40 cm Â 15 cm cage.
Statistical analysis. We presented data as means ± s.e.m. We used an independent t-test with a significance level of 0.05 to test differences between mdx and WT mice. When we made multiple comparisons between WT mice, mdx mice treated with vehicle and mdx mice treated with S107, we used a Bonferroni adjustment with a pair-wise significance level of 0.015.
Note: Supplementary information is available on the Nature Medicine website.
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